Implementation and Effectiveness Trial of HN-STAR Read more about Implementation and Effectiveness Trial of HN-STAR
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers Read more about A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer Read more about A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer Read more about XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Read more about A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Read more about Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer Read more about Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Read more about Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH Read more about A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH Read more about A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH